This product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human NCI-H1299 lung adenocarcinoma cell line, featuring targeted disruption of the BTN1A1 gene. The polyclonal format yields a heterogeneous mixture of cells with gene disruption, minimizing clonal variability and facilitating robust functional analyses. Cells are supplied as a live, adherent culture ready for use in immunological and cancer biology studies.
The NCI-H1299 cell line was derived from the lymph node metastasis of a lung adenocarcinoma from a 43-year-old Caucasian male, and it is a well-established model for non-small cell lung cancer (NSCLC) metastasis. This epithelial line retains key metastatic properties and is commonly used to investigate tumor-immune interactions and the molecular mechanisms underlying lung cancer progression.
BTN1A1 is an immune checkpoint molecule that suppresses T cell activation by interacting with an as-yet-unidentified T cell receptor, leading to reduced TCR signaling. It associates with TCR complex components such as CD3 and ZAP70, and recruits SHP-1/SHP-2 phosphatases to attenuate proximal signaling, diminishing LAT and NF-??B activation and ultimately reducing IL-2 production and promoting T cell anergy. BTN1A1 expression is regulated by IFN-??, TNF-??, and NF-??B, and it cooperates with other butyrophilin family members like BTN3A1 to modulate immune responses.
In the context of NCI-H1299 lung cancer cells, BTN1A1 knockout is anticipated to relieve immune suppression, potentially restoring T cell effector functions and enhancing anti-tumor immunity. This model allows dissection of tumor-intrinsic immunomodulatory roles of BTN1A1, and it may reveal how disruption of BTN1A1 alters NF-??B signaling and cytokine expression profiles within cancer cells, influencing the tumor microenvironment and metastatic behavior.
These polyclonal knockout cells are suited for a variety of research applications, including co-culture assays with T cells to assess activation markers (CD69, CD25) by flow cytometry, quantification of IL-2 and IFN-?? secretion by ELISA, and phospho-signaling analysis of ZAP70 and LAT. Additional uses include migration, invasion, and apoptosis assays, Western blotting, and RT-qPCR for downstream targets. This model supports immune checkpoint functional studies, cancer immunotherapy target validation, and investigation of autoimmune disease mechanisms. For further technical details or to request customization, please contact Ascent Research.
